NASDAQ:TGTX - TG Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.65 -0.10 (-0.73 %)
(As of 05/27/2018 08:02 AM ET)
Previous Close$13.65
Today's Range$13.50 - $14.00
52-Week Range$7.25 - $17.35
Volume514,875 shs
Average Volume801,412 shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.21

About TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics logoTG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Receive TGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TGTX
CUSIPN/A
Phone212-554-4484

Debt

Debt-to-Equity RatioN/A
Current Ratio3.51
Quick Ratio3.51

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$150,000.00
Price / Sales6,877.78
Cash FlowN/A
Price / CashN/A
Book Value$1.13 per share
Price / Book12.08

Profitability

EPS (Most Recent Fiscal Year)($1.91)
Net Income$-118,470,000.00
Net Margins-87,025.00%
Return on Equity-170.83%
Return on Assets-125.58%

Miscellaneous

Employees75
Outstanding Shares75,580,000

TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions

What is TG Therapeutics' stock symbol?

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

How were TG Therapeutics' earnings last quarter?

TG Therapeutics, Inc (NASDAQ:TGTX) released its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.15. The biopharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 87,025.00% and a negative return on equity of 170.83%. View TG Therapeutics' Earnings History.

What price target have analysts set for TGTX?

6 brokers have issued 12 month target prices for TG Therapeutics' shares. Their forecasts range from $23.00 to $33.00. On average, they anticipate TG Therapeutics' share price to reach $27.75 in the next twelve months. View Analyst Ratings for TG Therapeutics.

What are Wall Street analysts saying about TG Therapeutics stock?

Here are some recent quotes from research analysts about TG Therapeutics stock:
  • 1. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (5/10/2018)
  • 2. Raymond James analysts commented, "We are maintaining our Strong Buy rating for TG Therapeutics. Today, at the American Academy of Neurology (AAN) 70th Annual Meeting, the company provided an update on the ongoing Phase II study of TG-1101 (ublituximab) in patients with relapsing forms of multiple sclerosis (RMS)." (4/25/2018)
  • 3. HC Wainwright analysts commented, "TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors TG licenses novel BTK inhibitors that demonstrate superior selectivity to BTK in comparison to ibrutinib in the preclinical setting. On the morning of January 8, TG Therapeutics announced that it has entered into an exclusive global license agreement with Jiangsu Hengrui Medicine, pursuant to which TG will obtain worldwide rights, excluding Asia but including Japan, for the development of Hengrui’s BTK inhibitor program. The program includes TG-1701 and TG-1702, both of which are orally-available, covalently-bound BTK inhibitors." (1/8/2018)

Who are some of TG Therapeutics' key competitors?

Who are TG Therapeutics' key executives?

TG Therapeutics' management team includes the folowing people:
  • Mr. Michael S. Weiss, Exec. Chairman, Chief Exec. Officer and Pres (Age 52)
  • Mr. Sean A. Power CPA, Chief Financial Officer, Corp. Sec. and Treasurer (Age 36)
  • Jenna Bosco, Director of Investor Relations

Has TG Therapeutics been receiving favorable news coverage?

Media coverage about TGTX stock has been trending positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TG Therapeutics earned a media sentiment score of 0.42 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.47 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Who are TG Therapeutics' major shareholders?

TG Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (6.92%), BlackRock Inc. (4.60%), Franklin Resources Inc. (3.19%), Columbus Circle Investors (1.01%), Northern Trust Corp (0.83%) and Point72 Asset Management L.P. (0.80%). Company insiders that own TG Therapeutics stock include Laurence N Charney, Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.

Which major investors are selling TG Therapeutics stock?

TGTX stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, JPMorgan Chase & Co., Artal Group S.A., Guggenheim Capital LLC, Franklin Resources Inc., Citigroup Inc., United Capital Financial Advisers LLC and BB&T Securities LLC. View Insider Buying and Selling for TG Therapeutics.

Which major investors are buying TG Therapeutics stock?

TGTX stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Point72 Asset Management L.P., Highland Capital Management LP, Millennium Management LLC, Opaleye Management Inc., Columbus Circle Investors, Eversept Partners LLC and UBS Group AG. View Insider Buying and Selling for TG Therapeutics.

How do I buy shares of TG Therapeutics?

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TG Therapeutics' stock price today?

One share of TGTX stock can currently be purchased for approximately $13.65.

How big of a company is TG Therapeutics?

TG Therapeutics has a market capitalization of $1.03 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-118,470,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics employs 75 workers across the globe.

How can I contact TG Therapeutics?

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]


MarketBeat Community Rating for TG Therapeutics (TGTX)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  156 (Vote Underperform)
Total Votes:  559
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TG Therapeutics (NASDAQ:TGTX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for TG Therapeutics in the last 12 months. Their average twelve-month price target is $27.75, suggesting that the stock has a possible upside of 103.30%. The high price target for TGTX is $33.00 and the low price target for TGTX is $23.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.75$27.75$27.3571$28.6250
Price Target Upside: 103.30% upside93.38% upside186.46% upside246.97% upside

TG Therapeutics (NASDAQ:TGTX) Consensus Price Target History

Price Target History for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/25/2018Raymond JamesReiterated RatingBuyLowView Rating Details
3/9/2018B. RileyReiterated RatingBuy ➝ Buy$21.50 ➝ $27.00MediumView Rating Details
1/16/2018HC WainwrightReiterated RatingBuy$33.00LowView Rating Details
10/3/2017SunTrust BanksReiterated RatingBuy$28.00MediumView Rating Details
6/17/2017FBR & CoReiterated RatingBuyLowView Rating Details
6/5/2017Jefferies GroupReiterated RatingBuy$23.00MediumView Rating Details
3/8/2017Ladenburg ThalmannSet Price TargetBuy$30.00LowView Rating Details
3/7/2017Langenberg & CompanyBoost Price TargetPositive$28.00 ➝ $30.00N/AView Rating Details
2/22/2017AegisInitiated CoverageBuy$26.00N/AView Rating Details
12/7/2016Roth CapitalSet Price TargetBuy$33.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$28.00N/AView Rating Details
8/24/2016S&P Equity ResearchLower Price Target$7.15 ➝ $6.40N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

TG Therapeutics (NASDAQ:TGTX) Earnings History and Estimates Chart

Earnings by Quarter for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ:TGTX) Earnings Estimates

2018 EPS Consensus Estimate: ($1.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.48)($0.48)($0.48)
Q2 20182($0.57)($0.48)($0.53)
Q3 20182($0.51)($0.44)($0.48)
Q4 20182($0.53)($0.45)($0.49)

TG Therapeutics (NASDAQ TGTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.44)($0.59)$0.04 million$0.04 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.46)($0.46)$0.04 million$0.04 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.43)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.45)$0.04 million$0.04 millionViewListenView Earnings Details
5/5/2017Q1 2017($0.42)($0.52)$0.04 million$0.04 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.39)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
11/7/2016Q3($0.31)($0.50)$0.04 million$0.04 millionViewListenView Earnings Details
8/8/2016Q2($0.29)($0.33)$0.04 million$0.04 millionViewN/AView Earnings Details
5/10/2016Q1($0.36)($0.28)$0.04 million$0.04 millionViewListenView Earnings Details
3/7/2016Q4($0.32)($0.37)$38.10 million$38.10 millionViewN/AView Earnings Details
11/9/2015Q3($0.34)($0.28)$0.04 million$0.04 millionViewN/AView Earnings Details
8/10/2015Q215($0.32)($0.38)$0.22 million$0.04 millionViewListenView Earnings Details
5/4/2015Q115($0.33)($0.39)$0.04 million$0.04 millionViewN/AView Earnings Details
3/11/2015Q414($0.26)($0.48)$0.04 million$0.04 millionViewN/AView Earnings Details
11/10/2014Q214($0.32)($0.51)$0.04 million$0.04 millionViewN/AView Earnings Details
7/21/2014($0.28)($0.36)$0.04 million$0.04 millionViewN/AView Earnings Details
5/12/2014Q114($0.19)($0.25)$0.04 million$0.04 millionViewN/AView Earnings Details
3/5/2014Q413($0.18)($0.19)$40.00 million$38.10 millionViewN/AView Earnings Details
11/11/2013Q313($0.22)($0.62)$0.03 million$0.0381 millionViewN/AView Earnings Details
8/1/2013Q213($0.16)($0.29)$0.04 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.14)($0.17)$0.04 million$0.04 millionViewN/AView Earnings Details
3/21/2013Q4 2012($0.13)($0.04)ViewN/AView Earnings Details
11/8/2012Q3 2012($0.12)($0.16)ViewN/AView Earnings Details
11/14/2011Q3 2011($23.37)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

TG Therapeutics (NASDAQ:TGTX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

TG Therapeutics (NASDAQ TGTX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.70%
Institutional Ownership Percentage: 50.98%
Insider Trading History for TG Therapeutics (NASDAQ:TGTX)
Insider Trading History for TG Therapeutics (NASDAQ:TGTX)

TG Therapeutics (NASDAQ TGTX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Sean A PowerCFOSell32,006$8.50$272,051.00517,464View SEC Filing  
6/19/2017Sean A PowerCFOSell59,976$11.09$665,133.84477,464View SEC Filing  
4/11/2017William James KennedyDirectorSell8,548$10.27$87,787.96View SEC Filing  
4/4/2017Laurence N. CharneyDirectorSell7,000$11.17$78,190.00View SEC Filing  
1/4/2017Sean A. PowerCFOSell8,816$4.55$40,112.80View SEC Filing  
4/18/2016Sean A PowerCFOSell10,000$10.12$101,200.00466,682View SEC Filing  
1/5/2016Sean A PowerCFOSell22,790$11.21$255,475.90476,682View SEC Filing  
7/8/2015William James KennedyDirectorSell17,000$17.08$290,360.00View SEC Filing  
7/1/2015Sean A PowerCFOSell50,054$16.46$823,888.84View SEC Filing  
4/2/2015Sean A PowerCFOSell23,800$15.50$368,900.00View SEC Filing  
1/7/2015Sean A PowerCFOSell66,401$16.40$1,088,976.40View SEC Filing  
1/5/2015Sean A PowerCFOSell54,057$16.40$886,534.80View SEC Filing  
12/16/2014Michael S WeissMajor ShareholderSell210,618$16.44$3,462,559.92View SEC Filing  
12/16/2014Sean A PowerCFOSell38,041$16.44$625,394.04View SEC Filing  
12/11/2013Michael Weissmajor shareholderBuy10,000$3.43$34,300.007,839,471View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TG Therapeutics (NASDAQ TGTX) News Headlines

Source:
DateHeadline
Zacks: Analysts Expect TG Therapeutics, Inc (TGTX) Will Announce Quarterly Sales of $40,000.00Zacks: Analysts Expect TG Therapeutics, Inc (TGTX) Will Announce Quarterly Sales of $40,000.00
www.americanbankingnews.com - May 20 at 7:28 AM
Notable Friday Option Activity: MUR, AA, TGTXNotable Friday Option Activity: MUR, AA, TGTX
www.nasdaq.com - May 19 at 9:13 AM
TG Therapeutics: Assessing The Investment Prospects Of A Potential Big WinnerTG Therapeutics: Assessing The Investment Prospects Of A Potential Big Winner
seekingalpha.com - May 18 at 10:29 AM
Zacks: Brokerages Expect TG Therapeutics, Inc (TGTX) to Post -$0.55 EPSZacks: Brokerages Expect TG Therapeutics, Inc (TGTX) to Post -$0.55 EPS
www.americanbankingnews.com - May 18 at 1:24 AM
TG Therapeutics (TGTX) Announces Upcoming Data Presentations at ASCO and EHATG Therapeutics (TGTX) Announces Upcoming Data Presentations at ASCO and EHA
www.streetinsider.com - May 17 at 4:40 PM
TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology AssociationTG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association
finance.yahoo.com - May 17 at 9:21 AM
TG Therapeutics (TGTX) Rating Increased to Hold at BidaskClubTG Therapeutics (TGTX) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - May 16 at 3:46 PM
TG Therapeutics, Inc Expected to Earn Q2 2018 Earnings of ($0.48) Per Share (TGTX)TG Therapeutics, Inc Expected to Earn Q2 2018 Earnings of ($0.48) Per Share (TGTX)
www.americanbankingnews.com - May 14 at 1:21 AM
TG Therapeutics, Inc (TGTX) Expected to Post Q2 2018 Earnings of ($0.57) Per ShareTG Therapeutics, Inc (TGTX) Expected to Post Q2 2018 Earnings of ($0.57) Per Share
www.americanbankingnews.com - May 11 at 9:01 AM
Zacks Investment Research Lowers TG Therapeutics (TGTX) to SellZacks Investment Research Lowers TG Therapeutics (TGTX) to Sell
www.americanbankingnews.com - May 10 at 1:02 PM
Edited Transcript of TGTX earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of TGTX earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 9:27 AM
SunTrust Banks Analysts Cut Earnings Estimates for TG Therapeutics, Inc (TGTX)SunTrust Banks Analysts Cut Earnings Estimates for TG Therapeutics, Inc (TGTX)
www.americanbankingnews.com - May 10 at 9:18 AM
Stock Traders Buy Large Volume of Put Options on TG Therapeutics (TGTX)Stock Traders Buy Large Volume of Put Options on TG Therapeutics (TGTX)
www.americanbankingnews.com - May 10 at 7:40 AM
TG Therapeutics (TGTX) Issues  Earnings Results, Misses Expectations By $0.15 EPSTG Therapeutics (TGTX) Issues Earnings Results, Misses Expectations By $0.15 EPS
www.americanbankingnews.com - May 9 at 2:38 PM
TG Therapeutics misses by $0.15, revenue in-lineTG Therapeutics misses by $0.15, revenue in-line
seekingalpha.com - May 8 at 9:13 AM
TG Therapeutics: 1Q Earnings SnapshotTG Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 9:13 AM
TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial ResultsTG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 9:13 AM
TG Therapeutics, Inc (TGTX) Given Average Rating of "Buy" by BrokeragesTG Therapeutics, Inc (TGTX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 6 at 7:41 PM
TG Therapeutics (TGTX) Downgraded by BidaskClub to "Sell"TG Therapeutics (TGTX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - May 5 at 6:37 AM
 Analysts Expect TG Therapeutics, Inc (TGTX) Will Post Quarterly Sales of $40,000.00 Analysts Expect TG Therapeutics, Inc (TGTX) Will Post Quarterly Sales of $40,000.00
www.americanbankingnews.com - May 2 at 3:00 AM
Zacks: Analysts Anticipate TG Therapeutics, Inc (TGTX) Will Post Earnings of -$0.46 Per ShareZacks: Analysts Anticipate TG Therapeutics, Inc (TGTX) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - April 30 at 1:16 PM
TG Therapeutics (TGTX) Lifted to "Hold" at BidaskClubTG Therapeutics (TGTX) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - April 27 at 11:56 AM
TG Therapeutics (TGTX) "Buy" Rating Reaffirmed at Raymond JamesTG Therapeutics' (TGTX) "Buy" Rating Reaffirmed at Raymond James
www.americanbankingnews.com - April 25 at 10:49 AM
TG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with MS at AANTG Therapeutics (TGTX) Announces Updated Results from Ongoing Phase 2 Study of Ublituximab in Patients with MS at AAN
www.streetinsider.com - April 25 at 9:41 AM
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual MeetingTG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting
finance.yahoo.com - April 24 at 4:36 PM
TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1
www.nasdaq.com - April 24 at 9:10 AM
Data on now up to 48 patients through 24 weeks confirms previously reported positive resultsData on now up to 48 patients through 24 weeks confirms previously reported positive results
globenewswire.com - April 24 at 9:10 AM
TG Therapeutics (TGTX) Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at AACRTG Therapeutics (TGTX) Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at AACR
www.streetinsider.com - April 19 at 4:49 PM
Raymond James Reiterates "Buy" Rating for TG Therapeutics (TGTX)Raymond James Reiterates "Buy" Rating for TG Therapeutics (TGTX)
www.americanbankingnews.com - April 19 at 11:46 AM
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys BET Inhibitor, TG-1601, at the 2018 ...TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company's BET Inhibitor, TG-1601, at the 2018 ...
globenewswire.com - April 19 at 9:31 AM
TG Therapeutics (TGTX) Stock Rating Upgraded by Zacks Investment ResearchTG Therapeutics (TGTX) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 2:58 PM
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual MeetingTG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 18 at 9:35 AM
 Analysts Anticipate TG Therapeutics Inc (TGTX) Will Announce Quarterly Sales of $40,000.00 Analysts Anticipate TG Therapeutics Inc (TGTX) Will Announce Quarterly Sales of $40,000.00
www.americanbankingnews.com - April 15 at 3:45 AM
Q2 2018 Biotech Catalyst Watchlist: Phase 3 Clinical TrialsQ2 2018 Biotech Catalyst Watchlist: Phase 3 Clinical Trials
seekingalpha.com - April 13 at 4:43 PM
 Analysts Expect TG Therapeutics Inc (TGTX) Will Post Earnings of -$0.46 Per Share Analysts Expect TG Therapeutics Inc (TGTX) Will Post Earnings of -$0.46 Per Share
www.americanbankingnews.com - April 13 at 1:10 PM
TG Therapeutics Inc (TGTX) Receives Average Rating of "Buy" from AnalystsTG Therapeutics Inc (TGTX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 11 at 5:43 PM
BidaskClub Lowers TG Therapeutics (TGTX) to SellBidaskClub Lowers TG Therapeutics (TGTX) to Sell
www.americanbankingnews.com - April 10 at 3:25 PM
TG Therapeutics (TGTX) Buy Rating Reaffirmed at SunTrust BanksTG Therapeutics' (TGTX) Buy Rating Reaffirmed at SunTrust Banks
www.americanbankingnews.com - April 8 at 10:08 AM
TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare ConferenceTG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference
finance.yahoo.com - April 3 at 9:26 AM
TG Therapeutics (TGTX) Raised to Buy at ValuEngineTG Therapeutics (TGTX) Raised to Buy at ValuEngine
www.americanbankingnews.com - April 2 at 11:28 PM
Edited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMTEdited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMT
finance.yahoo.com - April 1 at 9:19 AM
TG Therapeutics (TGTX) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowTG Therapeutics (TGTX) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 30 at 9:17 AM
$40,000.00 in Sales Expected for TG Therapeutics Inc (TGTX) This Quarter$40,000.00 in Sales Expected for TG Therapeutics Inc (TGTX) This Quarter
www.americanbankingnews.com - March 29 at 4:54 AM
TG Therapeutics Inc (TGTX) Sees Large Decline in Short InterestTG Therapeutics Inc (TGTX) Sees Large Decline in Short Interest
www.americanbankingnews.com - March 29 at 2:21 AM
The 7 Best Stocks From Each Sector of Q1The 7 Best Stocks From Each Sector of Q1
investorplace.com - March 28 at 4:38 PM
HC Wainwright Reiterates "Buy" Rating for TG Therapeutics (TGTX)HC Wainwright Reiterates "Buy" Rating for TG Therapeutics (TGTX)
www.americanbankingnews.com - March 28 at 12:58 PM
TG Therapeutics (TGTX) Downgraded to "Hold" at BidaskClubTG Therapeutics (TGTX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - March 28 at 11:04 AM
TG Therapeutics (TGTX) Stock Rating Lowered by BidaskClubTG Therapeutics (TGTX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 26 at 10:59 PM
TG Therapeutics (TGTX) Upgraded at BidaskClubTG Therapeutics (TGTX) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 12:28 PM
TG Therapeutics (TGTX) CEO Michael Weiss on Q4 2017 Results - Earnings Call TranscriptTG Therapeutics' (TGTX) CEO Michael Weiss on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 18 at 9:39 AM

SEC Filings

TG Therapeutics (NASDAQ:TGTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TG Therapeutics (NASDAQ:TGTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TG Therapeutics (NASDAQ TGTX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.